Synthesis of Delgocitinib

Significance: Delgocitinib is a Janus kinase inhibitor that has been approved in Japan for the treatment of atopic dermatitis. The FDA has granted Fast Track Designation to delgocitinib cream for the treatment of adult moderate-to-severe chronic hand eczema.

Comment: The route to delgocitinib depicted delivered the API in 39% overall yield in nine steps without recourse to cryogenic conditions or chromatographic purification. This route has been implemented on a 60 kg scale.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2021, 17(05), 0479Published online: 20.04.2021DOI: 10.1055/s-0040-1719790; Reg-No.: K02021SF